Innate Pharma (XPAR:IPH) Debt-to-Asset : 0.23 (As of Jun. 2024)

View and export this data going back to 2006. Start your Free Trial

What is Innate Pharma Debt-to-Asset?

Innate Pharma's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €8.93 Mil. Innate Pharma's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was €26.57 Mil. Innate Pharma's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2024 was €151.50 Mil. Innate Pharma's debt to asset for the quarter that ended in Jun. 2024 was 0.23.

Innate Pharma Debt-to-Asset Historical Data

The historical data trend for Innate Pharma's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Innate Pharma Debt-to-Asset Chart

Innate Pharma Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Asset

Get a 7-Day Free Trial

0.05

0.06

0.17

0.20

0.22

Innate Pharma Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Debt-to-Asset	Get a 7-Day Free Trial															0.16	0.20	0.20	0.22	0.23

Competitive Comparison of Innate Pharma's Debt-to-Asset

For the Biotechnology subindustry, Innate Pharma's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Innate Pharma's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Innate Pharma's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Innate Pharma's Debt-to-Asset falls into.

Innate Pharma Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Innate Pharma's Debt-to-Asset for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(8.936	+	30.957)	/	184.193
	=	0.22

Innate Pharma's Debt-to-Asset for the quarter that ended in Jun. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(8.929	+	26.574)	/	151.497
	=	0.23

Innate Pharma (XPAR:IPH) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Innate Pharma Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Innate Pharma's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Innate Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Innate Pharma SA (XPAR:IPH) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

IPHYF:USA IPHA:USA 0EVI:UK IDDA:Germany IDD:Germany IDD:Germany

Address

117, Avenue de Luminy, Marseille, FRA, 13009

Website

https://www.innate-pharma.com

Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.

Innate Pharma Headlines

No Headlines